TSC2 and hamartoma: However, not all hamartomas found in patients with TSC reliably demonstrate loss of heterozygosity, suggesting that haploinsufficiency, post-translational inactivation of remaining protein, or dominant negative activities of mutant TSC1 (hamartin) or TSC2 (tuberin) may also underlie some disease phenotypes [8–10].